^
    Back
    Association details:
    Biomarker:MUTYH Y179C + MUTYH G396D
    Cancer:Colorectal Cancer
    Drug:Opdivo (nivolumab) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Invest New Drugs
    Title:

    Efficacy of immune checkpoint blockade in MUTYH-associated hereditary colorectal cancer

    Published date:
    08/03/2019
    Excerpt:
    ...we administered nivolumab to a CRC patient who carried two inactive MUTYH alleles (p.Y179C and p.G396D) and previously experienced failure of chemotherapy. This experimental treatment resulted in a pronounced tumor response. 
    DOI:
    https://doi.org/10.1007/s10637-019-00842-z